Clinical Trials Browser

Terminated × Interventional × trametinib × Clear all

NCT03825289 2026-05-14

THREAD

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT05518110 2026-04-13

PaTcH

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1 Terminated

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT02097225 2024-10-16

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

22 enrolled 21 charts

Melanoma, Neoplasm Metastasis

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Phase 1/2 Terminated

9 enrolled 17 charts

Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03272464 2023-09-22

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Phase 1 Terminated

1 enrolled 6 charts

Melanoma

NCT04566133 2023-08-21

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Phase 2 Terminated

2 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

Neoplasms

NCT01912625 2023-05-06

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03087448 2022-12-27

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

Melanoma

NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Phase 2 Terminated

6 enrolled 3 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT02410863 2020-10-14

BOTTOM

Phase 2 Terminated

Melanoma

NCT03232892 2019-12-03

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT01958112 2019-05-31

GSK1120212+GSK2141795 for Cervical Cancer

Phase 2 Terminated

14 enrolled 10 charts

Uterine Cervical Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Melanoma, Neoplasms

NCT02258607 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Phase 1 Terminated

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

NCT02580708 2018-10-02

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01978236 2018-08-17

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Phase 2 Terminated

6 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01907815 2018-04-06

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Phase 2 Terminated

24 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01721603 2018-01-23

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Phase 2 Terminated

2 enrolled 7 charts

Melanoma

NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Phase 1 Terminated

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01701037 2017-06-23

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 2 Terminated

13 enrolled 13 charts

Melanoma

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

Phase 1 Terminated

Neoplasms